Epigenome-wide association studies for cancer biomarker discovery in circulating cell-free DNA: technical advances and challenges

Miljana Tanić and Stephan Beck

Since introducing the concept of epigenome-wide association studies (EWAS) in 2011, there has been a vast increase in the number of published EWAS studies in common diseases, including in cancer. These studies have increased our understanding of epigenetic events underlying carcinogenesis and have enabled the discovery of cancer-specific methylation biomarkers. In this mini-review, we have focused on the state of the art in EWAS applied to cell-free circulating DNA for epigenetic biomarker discovery in cancer and discussed associated technical advances and challenges, and our expectations for the future of the field.

Address
UCL Cancer Institute, University College London, London WC1E 6BT, UK

Corresponding author: Tanić, Miljana (m.tanic@ucl.ac.uk)

Introduction
The epigenome represents the compendium of (mitotically) heritable molecular changes, independent of alterations in the DNA sequence that holistically regulate (in concert with other factors) the mode of expression of the information encoded in the DNA sequence, hence determining the cellular phenotype [1]. Epigenetic marks include DNA methylation, histone modifications and variants as well gene expression regulation by ncRNAs. DNA methylation is one of the most important epigenetic modifications in eukaryotes necessary for cellular differentiation, with each cell type having a unique methylation profile. Environmental exposures, age-related changes and those induced by injury and inflammation, or mutations in epigenome-regulating genes, leave their mark on the methylome creating a distinctive footprint.

Analogous to genome-wide association studies (GWAS), epigenome-wide studies (EWAS) are designed to identify associations of epigenetic marks with a specific phenotype (trait, condition or a disease) using a variety of array-or sequencing-based profiling technologies [2]. The most commonly studied epigenetic mark is DNA methylation of 5-methylcytosine in CpG context. DNA methylation plays a crucial role in gene regulation of many oncogenes and tumour suppressor genes, and aberrant DNA methylation of both individual gene promoters and on a genome-wide scale has been heavily implicated in cancer initiation and progression [3,4].

Hypermethylation of promoter CpG islands may induce epigenetic silencing of individual tumour suppressor genes while global hypomethylation contributes to tumourigenesis through the promotion of genomic instability and activation of oncogenes. It has been well documented that specific epigenetic changes, such as MGMT promoter hypermethylation in glioblastoma, or global hypermethylation in bladder cancer, have been associated with sensitivity/resistance to chemotherapeutic drugs [5–7]. Alterations in DNA methylation patterns were shown to be an early feature in cancer development, and unlike mutations, specific epimutations are highly prevalent within tumour types [8–11]. Pronounced intra-tumour heterogeneity of promoter DNA methylation has been documented in a variety of tumours, and recent studies have demonstrated a positive correlation between the extent of genome-wide DNA methylation heterogeneity and adverse patient outcome [12–14]. Altogether, these findings have spurred research into the potential use of specific DNA methylation alterations as cancer biomarkers for diagnosis, prognosis and prediction of therapy response, and early detection [15–17].

Cancer EWAS and biomarkers
The scope for the discovery of novel DNA methylation biomarkers has greatly expanded due to the evolution of new technologies enabling a transition from candidate-gene approaches to genome-wide studies based on micro-array and sequencing methods interrogating hundreds of thousands of CpG loci, and ultimately to bisulfite sequencing of the whole genome or a selected fraction of the genome. EWAS have provided a systematic insight into both environmental (such as diet and smoking), and intrinsic factors that result in altered DNA methylation profiles. Although the causal relationship cannot be inferred with certainty from EWAS, DNA methylation marks strongly associated with the phenotype of interest can, nevertheless, be useful as cancer biomarkers [15,18].
In the past five years, as a result of a widespread use of Infinium Bead Array (‘450 K array’) and methylation pull-down sequencing assays, the number of EWAS studies aimed at identifying and validating specific DNA methylation changes associated with cancer initiation, specific subtypes, prognosis or drug response published each year has tripled [17]. Many DNA methylation biomarkers with diagnostic, prognostic and predictive power are already in clinical trials or the clinical setting for cancer [19]. One such success story for DNA methylation biomarker development, with rapid translation from bench to bedside, is the methylation of the SEPT9 promoter as implemented in a blood-based test for colorectal cancer (CRC) screening [20]. Following extensive validation in prospective clinical trials, the SEPT9 test has been commercially marketed as Epiprocolon (Epigenomics AG) and been made available in several European countries, China and USA where it has been recently approved by the US Food and Drug Administration (FDA).

**DNA sources for EWAS**

Given the robustness of DNA methylation during cell isolation and processing, DNA derived from almost any tissue type or bodily fluid can be used for DNA methylation analysis, provided there is enough input material for the chosen assay. Figure 1 illustrates the most common cell-based and cell-free DNA sources used for EWAS and why. Although it is desirable to measure disease-associated DNA methylation biomarkers in a disease-relevant tissue or primary cell type, surrogate tissues such as whole blood may be used if the biomarker is tightly associated with the phenotype of interest either directly or indirectly. Whole blood has been commonly used as a surrogate tissue of choice for many EWAS studies performed to date despite limitations in detecting tissue-specific alterations and the requirement to correct for cell composition heterogeneity reviewed in [21,22]. A notable early example of a blood-based EWAS applying cell composition correction is a study by Liu et al. in which they identified four CpG loci in the major histocompatibility complex (MHC) cluster associated with rheumatoid arthritis by analysing 354 cases and 337 healthy controls using the 450 K array platform [23]. Other types of tissues, including solid tumour biopsies, have also been successfully used to identify biomarkers as well as mechanistically relevant differentially methylated positions (DMRs) and regions (DMRs), in lung cancer [24], osteosarcoma [25], Wilms tumour [26], penile carcinoma [27], glioblastoma [28], neuroblastoma [29] and cervical carcinoma [30] to name but a few recent studies. However, for successful discovery of biomarkers based on comparing (preferably matched) tumour and normal tissue samples, and subsequent translation to a blood-based test suitable for a clinical environment, it is important to include whole blood as a control tissue and/or screen the biomarker against an appropriate database such as MARMAL-AID [31,32]. This will ensure that selected cancer-specific biomarkers will not be or only be minimally confounded by cell composition effects.

**Liquid biopsies for biomarker discovery**

Because of their invasive nature, tumour biopsies cannot always be performed in the clinical setting and; additionally, they are liable to sampling bias owing to the heterogeneous nature of solid tumours. To overcome these limitations, liquid biopsies are increasingly being used as a minimally invasive alternative and more comprehensive capture of tumour heterogeneity [33]. For that, circulating tumour (ctDNA) or cell-free DNA (cfDNA) isolated from different biofluids, such as plasma, serum, urine or saliva can be used for biomarker discovery in the context of tissue [34,35] and tumour [36,37] dynamics, including tissue-specific cell death as well as tumour load, progression and evolution (Figure 1).

Cell-free DNA is highly fragmented to a mean length of only around 180 base pairs. Components of cfDNA include DNA shed by normal cells undergoing apoptosis in healthy individuals, but both necrosis and apoptosis of tumour cells, disseminated tumour cells (DTC), and active secretion of DNA by living cells contribute to ctDNA in cancer patients. Although ctDNA makes up less than 1% of total cfDNA content, it can be distinguished from normal cfDNA by the presence of tumour specific chromosomal, genetic or epigenetic alterations [36,38,39].

The presence of detectable ctDNA was determined in early stage solid tumours across different cancer types, albeit at low quantities [40], and several studies
demonstrated the utility of ctDNA for monitoring tumour dynamics during treatment in patients with advanced disease. Exemplar proof-of-principle efforts include a study on metastatic breast cancer comparing the utility of targeted sequencing of ctDNA to serum cancer antigen 15-3 (CA15-3) and circulating tumour cells (CTCs) to measure treatment response [41], and a study by Murtaza and colleagues applying exome sequencing to track tumour evolution of breast, ovarian and lung cancers in response to therapy [42]. In contrast, most of the studies looking at cfDNA methylation associated with tumour stage, prognosis and response to therapy performed to date were based on candidate-gene approaches [43–47]. Studies based on genome-wide methylation profiling of cfDNA remain scarce [48*,49*,50*,51**] due to technical challenges including minute amounts of starting material, procedural losses during sample processing, DNA extraction, bisulfite conversion and library preparation (Figure 2).

**Technical challenges**

Although there is a plethora of available methods for genome-wide DNA methylation profiling, including the use of methylation-specific restriction enzymes, affinity enrichment or bisulfite conversion in combination with microarray or sequencing; these methods differ not only in their coverage and resolution (ranging from few 100s to 1 bp), but also require different amounts of starting material [52*,53]. The gold standard method for genome-wide interrogation of DNA methylation at a single base pair resolution with a digital readout is bisulfite sequencing (BS-seq) [54,55]. Here, we discuss the critical determinants for applying high-throughput genome-wide BS-seq to EWAS for cancer biomarker discovery in liquid biopsies (Figure 2).

Firstly, the choice of biofluid is of significant importance, and should be selected not only in relation to the biology of the disease (for instance, urine for bladder cancer, saliva for oral cancer, etc.), but also taking into consideration the composition of the sample. For example, even though blood serum contains higher concentrations of cfDNA per ml than plasma, it was demonstrated that large fraction of it originates from lysed lymphocytes and thus, contains reduced representation of ctDNA [49]. To achieve an optimal analytical sensitivity of the
Secondly, treatment of cfDNA with sodium bisulfite results in further fragmentation and significant loss of starting material during desulfonation and purification procedures [57–59]. Even though the levels of cfDNA are somewhat increased in cancer patients, the combination of minute amounts of tumour-specific methylated DNA circulating in the excess of unmethylated ‘normal’ cfDNA, and bisulfite treatment may lead to reduced complexity and stochastic sampling issues. In addition, the limiting factor for variant detection in cfDNA methylation analysis by BS-seq is the background noise from the incomplete bisulfite conversion, which might be further reduced by optimisation of this step. Thus, efficient protocols for cfDNA isolation from plasma and bisulfite treatment are critical factors for the subsequent generation of libraries of sufficient complexity and successful analysis of sparse amounts of methylated DNA in plasma.

Finally, standard BS-seq protocols, where adaptor tagging is preceding the bisulfite conversion step, followed by several gel purification steps resulting in a significant loss of starting material, require micrograms of input DNA and are not amenable for use on cfDNA. Other important considerations for the BS-Seq EWAS study design that are not the focus of this manuscript, are sample size, sequencing depth, and the choice of analysis pipelines that are described in greater detail elsewhere [32,60–65].

**Methods for ultra-low input WGBS**

Recently, new solutions have enabled a remarkable reduction of the required starting material to allow generation of fairly complex libraries for whole-genome (WGBS) bisulfite sequencing starting from tens of nanograms to subnanogram quantities of DNA [52*,66*,67*,68].

Ultra-low input bisulfite sequencing became feasible by incorporating bead-purification, single-tube library preparation, and engineering different methods for library construction based on: random priming of tagged adapters to bisulfite converted ssDNA, post-bisulfite adaptor tagging (PBAT) [69–71]; transposase-based library construction – Tagonmentation BS-seq (T-WGBS or Tn5mC-seq) [72–74]; ssDNA adaptor ligation originally applied to ancient DNA samples [75,76]; switching activity of MMLV-RT enzyme to introduce both adapters in a single step – Capture and Amplification by Tailing and Switching (CATS) [77]. These methods were successfully applied for whole-genome methylation profiling of single cells [78], maternal plasma for prenatal diagnostics [68], and plasma from cancer patients [50*,51**,79**].

**Targeted BS-seq of circulating cell-free DNA**

Preferably, EWAS would be performed using complete methylation data. For the time being, however, the costs associated with WGBS are still prohibitively high to allow for high-throughput studies despite recent progress in extracting more information from low depth-of-coverage WGBS data [80*].

Other approaches for medium- to high-coverage, targeted bisulfite sequencing, rely on the non-specific enrichment of CpG rich regions either by restriction-enzyme mediated as in the case of reduced representation bisulfite sequencing (RRBS), or target-specific enrichment. Modified RRBS methods were applied to study methylation in small cell populations [81,82], and in single cells [83]. Although RRBS was successfully applied to laser captured FFPE samples [84], it is yet to be determined if is amenable for use on highly fragmented cfDNA. In a recent study, Wen et al. implemented an innovative highly sensitive method for detection of thousands of hypermethylated CpG islands in cfDNA, methylated CpG tandem amplification and sequencing (MCTAS-Seq), to analyse a large cohort of tissue (n = 57) and plasma samples(n = 94) from hepatocellular carcinoma (HCC) patients (n = 36) and healthy controls (n = 55). A panel of four genes specific for cancer detection (RGS10, ST8SIA6, RUNX2 and VIM) was identified and comparison between matched plasma and tissue samples indicated that both the cancer and noncancerous tissues contribute to elevation of the methylation markers in plasma [85**].

Conversely, target-specific enrichment might be carried out using microdroplet PCR amplification (Raindance) [86,87], ligation capture [88,89], bisulfite padlock probe (BSPP) capture [90,91] or in-solution hybridization [92–94]. To the best of our knowledge, these enrichment methods were not yet applied to the genome-wide analysis of plasma cfDNA, due to the comparably high input requirements (few hundred nanograms to few micrograms). Nonetheless, Miura et al. have recently combined the PBAT protocol with in-solution hybridization using Agilent SureSelect probes to perform targeted bisulfite sequencing starting from only 30 ng of DNA [95]. With continuing research in the field, we believe that target enrichment in combination with aforementioned ultra-low input methods for library preparation, may prove highly suitable for future EWAS aimed at discovery of novel cfDNA methylation biomarkers.
Outlook
EWAS performed on liquid biopsies represents a highly promising and minimally invasive platform for discovery of novel epigenetic biomarkers for early detection, prognosis and treatment monitoring in cancer. Based on the compelling advantages and progress discussed here, it is not surprising to see both commercial and academic initiatives being set up leveraging different aspects of cell-free DNA analysis, including GrailBio (http://www.grailbio.com/), leveraging ultra-deep sequencing, CancerID (http://www.cancer-id.eu/), leveraging major pan-European resources, C2e [96], leveraging integration with whole-body imaging and UroMark, leveraging microdroplet technology [97], to name but a few. Following the recent benchmarking of DNA methylation assays for validating epigenetic biomarkers [98**] and the development of more sensitive methods overcoming the discussed technical limitations for genome-wide methylation analysis of cfDNA and ctDNA, we predict a surge in EWAS-based studies utilizing liquid biopsies in the coming years. Together with complementary approaches, these studies will advance precision medicine for cancer by facilitating the delivery of much-needed biomarkers for transforming cancer health care.

Conflict of interest
The authors have no competing interests to disclose.

Acknowledgements
The research leading to these results has received funding from the People Programme (Marie Curie Actions) of the European Union’s Seventh Framework Programme FP7/2007-2013/under REA grant agreement (608763); the Danish Council for Strategic Research (1309-00006B), the NIHR UCLH Biomedical Research Centre (BRC275/CN/SB/101330), the Wellcome Trust (99148) and a Royal Society Wolfson Research Merit Award (WM100023).

References and recommended reading
Papers of particular interest, published within the period of review, have been highlighted as:
• of special interest
•• of outstanding interest

1. Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A: An operational definition of epigenetics. Genes Dev 2009, 23:781-783.

2. Rakyan VK, Down TA, Balding DJ, Beck S: Epigenome-wide association studies for common human diseases. Nat Rev Genet 2011, 12:529-541.

3. Esteller M: Epigenetics in cancer. N Engl J Med 2008, 358:1148-1159.

4. Jones PA, Baylin SB: The epigenomics of cancer. Cell 2007, 128:683-692.

5. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000, 343:1350-1354.

6. Baylin SB: Resistance, epigenetics and the cancer ecosystem. Nat Med 2011, 17:288-289.

7. Brown R, Curry E, Magnani L, Wilhelm-Benartzi CS, Borley J: Pooled epigenetic states and acquired drug resistance in cancer. Nat Rev Cancer 2014, 14:747-753.

8. Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielsson E, Baylin SB, Herman JG: Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A 1998, 95:11891-11896.

9. Belinsky SA, Palmisano WA, Gilliland FD, Crooks LA, Divine KK, Winters SA, Grimes MJ, Harms HJ, Tellez CS, Smith TM et al.: Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 2002, 62:2370-2377.

10. irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Ouyang P, Cui H, Gabo K, Rongione M, Webster M et al.: The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 2009, 41:178-186.

11. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D et al.: CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006, 38:787-793.

12. Landau DA, Clement K, Ziller MJ, Boyle P, Fan J, Gu H, Stevenson K, Sougnez C, Wang L, Li S et al.: Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. Cancer Cell 2014, 26:813-825.

13. Pan H, Jiang Y, Boi M, Tabbo F, Redmond D, Nie K, Ladetto M, Chiappaella A, Cerchietti L, Shakovnik R et al.: Epigenomic evolution in diffuse large B-cell lymphomas. Nat Commun 2015, 6:6921.

14. Brock D, Assenov Y, Minner S, Bogatyrnova O, Simon R, Koop C, Oakes C, Zucknick M, Lipka DB, Weissenfeldt J et al.: Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer. Cell Rep 2014, 8:798-806.

15. Laird PW: The power and the promise of DNA methylation markers. Nat Rev Cancer 2003, 3:253-266.

16. Herceg Z, Hainaut P: Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis. Mol Oncol 2007, 1:26-41.

17. Mikeska T, Craig JM: DNA methylation biomarkers: cancer and beyond. Genes (Basel) 2014, 5:821-864.

18. Mikeska T, Bock C, Do H, Dobrovic A: DNA methylation biomarkers in cancer: progress towards clinical implementation. Expert Rev Mol Diagn 2012, 12:473-487.

19. Warton K, Mahon KL, Samimi G: Methylated circulating tumor DNA in blood: power in cancer prognosis and response. Endocr Relat Cancer 2016, 23:R157-R171.

A comprehensive review of circulating DNA methylation biomarkers for cancer prognosis and monitoring.

20. Payne SR: From discovery to the clinic: the novel DNA methylation biomarker (m)SEPT9 for the detection of colorectal cancer in blood. Epigenomics 2010, 2:575-585.

21. Michels KB, Binder AM, Dedeuwaerder S, Epstein CB, Greally JM, Gut I, Houseman EA, Izzii B, Kelsey KT, Meissner A et al.: Recommendations for the design and analysis of epigenome-wide association studies. Nat Methods 2013, 10:949-955.

22. Li L, Choi JY, Lee KM, Sung H, Park SK, Oze I, Pan KF, You WC, Chen YX, Fang JY et al.: DNA methylation in peripheral blood: a potential biomarker for cancer molecular epidemiology. J Epidemiol 2012, 22:384-394.

23. Liu Y, Areyee MJ, Padyukov L, Fallin MD, Hesselberg E, Runarsson A, Reinius L, Acevedo N, Taub M, Ronninger M et al.: Epigenome-wide association study implicates DNA methylation as an intermediary of genetic risk in rheumatoid arthritis. Nat Biotechnol 2013, 31:142-147.

24. Shenker NS, Polidoro S, van Veldhoven K, Saccardi C, Ricceri F, Birrell MA, Belvisi MG, Brown R, Vineis P, Flanagan JM:
Epigenome-wide association study in the European Prospective Investigation into Cancer and Nutrition (EPIC-Turin) identifies novel genetic loci associated with smoking. *Hum Mol Genet* 2013, 22:843-851.

26. Rosenblum JM, Wietjenga NA, Fazzari MJ, Krailo M, Barkauskas DA, Gorlick R, Greally JM: Predictive properties of DNA methylation patterns in primary tumor samples for osteosarcoma relapse status. *Epigenetics* 2015, 10:31-39.

27. Charlton J, Williams RD, Sebire NJ, Popov S, Vujanic G, Chaglati T, Alcaide-German M, Morris T, Butcher LM, Guilhamon P et al.: Comparative methylome analysis identifies new tumour subtypes and biomarkers for transformation of nephrogenic rests into Wilms tumour. *Genome Med* 2015, 7:11.

28. Kuanse H, Colus IM, Bussao AF, Hernandez-Vargas H, Barros-Filho MC, Marchi FA, Scapulatempo-Neto C, Faria EF, Lopes A, Guimaraes GC et al.: Genome-wide methylation and transcriptome analysis in penile carcinoma: uncovering new molecular markers. *Clin Epigenet* 2015, 7:46.

29. Mock A, Geisenberger C, Orik C, Warta R, Schwager C, Jungk C, Dutreul C, Geisehelt L, Weichenhan D, Zucknick M et al.: LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients. *Int J Cancer* 2016, 139:424-432.

30. Olsson M, Beck S, Kogner P, Martinsson T, Caren H: Genome-wide methylation profiling identifies novel methylated genes in neuroblastoma tissues. *Epigenetics* 2016, 11:74-81.

31. Wang R, van Leeuwen RW, Boers A, Klip HG, de Meyer T, Steenbergen RD, van Criekinge W, van der Zee AG, Schuureng E, Wiaman GB: Genome-wide methylome analysis using MethylCap-seq uncovers 4 hypermethylated markers with high sensitivity for both adenocarcinoma and squamous-cell cervical carcinoma. *Oncotarget* 2016, 7(December (49)):80735-80750.

32. Lowe R, Rakyan VK: Marmal-aid—a database for Infinium HumanMethylation450. *BMC Bioinform* 2013, 14:359.

33. Birney E, Smith GD, Greally JM: Epigenome-wide association studies and the interpretation of disease—omics. *PLoS Genet* 2012, 12:e1006105.

34. Crowley E, Di Nicotolantonio F, Loupakis F, Bardelli A: Liquid biopsy: monitoring cancer—genetics in the blood. *Nat Rev Clini Oncol* 2013, 10:472-484.

35. Snyder MW, Kircher M, Hill AJ, Daza RM, Shendure J: Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. *Cell* 2016, 164:57-66.

The authors generated maps of genome-wide in vivo nucleosome occupancy by deep sequencing cfDNA, showing that short cfDNA fragments harbor footprints of transcription factors that can be used to determine their tissues of origin.

36. Diaz LA Jr, Bardelli A: Liquid biopsies: genotyping circulating tumor DNA. *J Clin Oncol* 2014, 32:579-586.

37. Ignatiadis M, Dawson SJ: Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality? *Ann Oncol* 2014, 25:2304-2313.

38. Schwarzenbach H, Hoon DS, Pantel K: Cell-free nucleic acids as biomarkers in cancer patients. *Nat Rev Cancer* 2011, 11:426-437.

39. Jung K, Fleischhacker M, Rabien A: Cell-free DNA in the blood as a solid tumor biomarker—a critical appraisal of the literature. *Clin Chim Acta* 2010, 411:1611-1624.

40. Buttegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM et al.: Detection of circulating tumor DNA in early- and late-stage human malignancies. *Sci Transl Med* 2014, 6:224ra224.

41. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, Dunning MJ, Gale D, Forsythe T, Mahler-Araujo B et al.: Analysis of circulating tumor DNA to monitor metastatic breast cancer. *N Engl J Med* 2013, 368:1199-1209.

42. Murtaza M, Dawson SJ, Tsui DW, Gale D, Forsythe T, Piskorz AM, Parkinson C, Chin SF, Kingsbury Z, Wong AS et al.: Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. *Nature* 2013, 497:108-112.

43. Begum S, Brait M, Dasgupta S, Ostrow KL, Zahurak M, Carvalho AL, Califano JA, Goodman SN, Westra WH, Hoque MO et al.: An epigenetic marker panel for detection of lung cancer using cell-free serum DNA. *Clin Cancer Res* 2011, 17:4494-4503.

44. Wong IH, Johnson PJ, Lai PB, Lau WY, Lo YM: Tumor-derived epigenetic changes in the plasma and serum of liver cancer patients. Implications for cancer detection and monitoring. *Ann N Y Acad Sci* 2000, 906:102-105.

45. Iyer P, Zeki AR, Hung CW, Schieflbein E, Ismail K, Hablas A, Seifeldin IA, Soliman AS: Concordance of DNA methylation patterns in plasma and tumor DNA of Egyptian hepatocellular carcinoma patients. *Exp Mol Pathol* 2010, 88:107-111.

46. Fackler MJ, Lopez Bujanda Z, Umbricht C, Teo WW, Cho S, Zhang Z, Yaspanathan K, Jeter S, Argani P, Wang C et al.: Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer. *Cancer Res* 2014, 74:2160-2170.

47. Vaca-Paniagua F, Oliver J, Noqueira da Costa A, Merie P, McKay J, Herceg Z, Holmlia R: Targeted deep DNA methylation analysis of circulating cell-free DNA in plasma using massively parallel semiconductor sequencing. *Epigenomics* 2015, 7:353-362.

48. Zhao Y, Xue F, Sun J, Guo S, Zhang H, Qiu B, Geng J, Gu J, Zhou X, Wang W et al.: Genome-wide methylation profiling of the different stages of hepatitis B virus-related hepatocellular carcinoma development in plasma cell-free DNA reveals potential biomarkers for early detection and high-risk monitoring of hepatocellular carcinoma. *Clin Epigenet* 2014, 6:30.

In this study, the authors performed genome-wide methylation profiling of pooled plasma cfDNA samples by MethylCap-seq to evaluate changes in methylation during progression of hepatocellular carcinoma.

49. Worton K, Lin V, Navin T, Armstrong NJ, Kaplan W, Ying K, Gloss B, Mangh H, Natar SS, Hacker NF et al.: Methylation-capture and next-generation sequencing of free circulating DNA from human plasma. *BM C Genom* 2014, 15:476.

In this study the authors employed authors employed modified affinity enrichment protocol for DNA methylation profiling (MBD-cap seq) in plasma samples.

50. Chan KC, Jiang P, Chan CW, Sun K, Wong J, Hui EP, Chan SL, Chan WC, Hui DS, Ng SS et al.: Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. *Proc Natl Acad Sci U S A* 2013, 110:18761-18768.

In this study the authors demonstrated that the detection of genome-wide hypomethylation and copy number aberrations in plasma using WGBS is a promising approach for hepatocellular carcinoma detection.

51. Legendre C, Gooden GC, Johnson K, Martinez RA, Liang WS, Saliba B: Whole-genome bisulfite sequencing of cell-free DNA identifies signature associated with metastatic breast cancer. *Clin Epigenet* 2015, 7:100.

In this study the authors performed EWAS based on WGBS of cfDNA, to identify DNA hypermethylated loci for prediction of metastatic breast cancer.

52. Plongthongkum N, Diep DH, Zhang K: Advances in the profiling of DNA modifications: cytosine methylation and beyond. *Nat Rev Genet* 2014, 15:447-461.

This very detailed review summarizes state-of-the-art whole-genome and targeted bisulfite sequencing methods.

53. Laird PW: Principles and challenges of genomewide DNA methylation analysis. *Nat Rev Genet* 2010, 11:191-203.
87. Paul DS, Guilhamon P, Karpathakis A, Butcher LM, Thirlwell C, Feber A, Beck S: Assessment of RainDrop BS-seq as a method for large-scale, targeted bisulfite sequencing. Epigenetics 2014, 9:678-684.

88. Nautiyal S, Carlton VE, Lu Y, Ireland JS, Flaucher D, Moorhead M, Gray JW, Spellman P, Mindrinos M, Berg P et al.: High-throughput method for analyzing methylation of CpGs in targeted genomic regions. Proc Natl Acad Sci U S A 2010, 107:12587-12592.

89. Varley KE, Mitra RD: Bisulfite Patch PCR enables multiplexed sequencing of promoter methylation across cancer samples. Genome Res 2010, 20:1279-1287.

90. Diep D, Plongthongkum N, Gore A, Fung HL, Shoemaker R, Zhang K: Library-free methylation sequencing with bisulfite padlock probes. Nat Methods 2012, 9:270-272.

91. Deng J, Shoemaker R, Xie B, Gore A, LeProust EM, Antosiewicz-Bourget J, Egli D, Maherali N, Park IH, Yu J et al.: Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming. Nat Biotechnol 2009, 27:353-360.

92. Lee EJ, Pei L, Srivastava G, Joshi T, Kushwaha G, Choi JH, Robertson KD, Wang X, Colbourne JK, Zhang L et al.: Targeted bisulfite sequencing by solution hybrid selection and massively parallel sequencing. Nucleic Acids Res 2011, 39:e127.

93. Ivanov M, Kais M, Kacevskas M, Metspaku A, Ingelman-Sundberg M, Milani L: In-solution hybrid capture of bisulfite-converted DNA for targeted bisulfite sequencing of 174 ADME genes. Nucleic Acids Res 2013, 41:e72.

94. Wang J, Jiang H, Ji G, Gao F, Wu M, Sun J, Luo H, Wu J, Wu R, Zhang X: High resolution profiling of human exon methylation by liquid hybridization capture-based bisulfite sequencing. BMC Genom 2011, 12:597.

95. Miura F, Ito T: Highly sensitive targeted methylome sequencing by post-bisulfite adaptor tagging. DNA Res 2015, 22:13-18.

96. Beck S, Ng T: C2c: turning cancer into chronic disease. Genome Med 2014, 6:38.

97. Feber A, Dhami P, Dong L, de Winter P, Tan WS, Martínez-Fernández M, Paul DS, Hynes-Allen A, Rezaee S, Gurung P et al.: UroMark-a urinary biomarker assay for the detection of bladder cancer. Clin Epigenetics 2017, 9:8(January (31)) http://dx.doi.org/10.1186/s13148-016-0303-5.

98. Bock CHF, Carmona FJ, Tierling S, Datlinger P, Assenov Y, **Berdasco M, Bergmann AK, Booher K, Busato F, Campan M et al.: Quantitative comparison of DNA methylation assays for large-scale validation and epigenetic biomarker development. Nat Biotechnol 2016, 34:726-737.

In this study, the authors performed a comprehensive benchmarking of currently available DNA methylation assays for biomarker validation studies.